These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 24021505)

  • 1. Pulsed intravenous administration of scopolamine produces rapid antidepressant effects and modest side effects.
    Furey ML; Zarate CA
    J Clin Psychiatry; 2013 Aug; 74(8):850-1. PubMed ID: 24021505
    [No Abstract]   [Full Text] [Related]  

  • 2. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial.
    Furey ML; Drevets WC
    Arch Gen Psychiatry; 2006 Oct; 63(10):1121-9. PubMed ID: 17015814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised, double-blind, active placebo-controlled, parallel groups, dose-response study of scopolamine hydrobromide (4-6 μg/kg) in patients with major depressive disorder.
    Chen JCC; Sumner RL; Krishnamurthy Naga V; Hoeh N; Ayeni HA; Singh V; Sundram F; Campbell D; Muthukumaraswamy S
    Trials; 2020 Feb; 21(1):157. PubMed ID: 32041658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Concurrent Treatment With Intravenous Ketamine and an Irreversible Monoamine Oxidase Inhibitor for Treatment-Resistant Depression Without Hypertensive Crises.
    Wang JCC; Swainson J
    J Clin Psychopharmacol; 2020; 40(5):515-517. PubMed ID: 32740556
    [No Abstract]   [Full Text] [Related]  

  • 5. Scopolamine produces larger antidepressant and antianxiety effects in women than in men.
    Furey ML; Khanna A; Hoffman EM; Drevets WC
    Neuropsychopharmacology; 2010 Nov; 35(12):2479-88. PubMed ID: 20736989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antidepressant treatment practice in the face of STAR*D and STEP-BD.
    Cassidy F
    Bipolar Disord; 2008 Dec; 10(8):973-4. PubMed ID: 19594512
    [No Abstract]   [Full Text] [Related]  

  • 7. Questionnaire survey on the prescribing practice of Japanese psychiatrists for mood disorders.
    Oshima A; Higuchi T; Fujiwara Y; Iida M; Iwanami A; Kanba S; Motohashi N; Uchitomi Y; Yamada K; Yamawaki S
    Psychiatry Clin Neurosci; 1999 Oct; 53 Suppl():S67-72. PubMed ID: 10560902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of scopolamine compared to placebo in individuals with bipolar disorder who are experiencing a depressive episode (SCOPE-BD): study protocol for a randomised double-blind placebo-controlled trial.
    Miravalles C; Kane R; McMahon E; McDonald C; Cannon DM; Hallahan B
    Trials; 2022 Apr; 23(1):339. PubMed ID: 35461262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The modern pharmacopoeia: a return to depressive realism?
    Goldberg JF
    Bipolar Disord; 2008 Dec; 10(8):969-72. PubMed ID: 19594511
    [No Abstract]   [Full Text] [Related]  

  • 10. Do no harm: a paradigm shift in the unchecked use of antidepressants.
    Morrissette DA
    CNS Spectr; 2017 Apr; 22(2):118-119. PubMed ID: 28179047
    [No Abstract]   [Full Text] [Related]  

  • 11. Upping the ante on antidepressants.
    Malhi GS
    Bipolar Disord; 2008 Dec; 10(8):975-8. PubMed ID: 19594513
    [No Abstract]   [Full Text] [Related]  

  • 12. Mixed features and mixed states in psychiatry: from calculus to geometry.
    McIntyre RS
    CNS Spectr; 2017 Apr; 22(2):116-117. PubMed ID: 28264727
    [No Abstract]   [Full Text] [Related]  

  • 13. [Interest of scopolamine as a treatment of major depressive disorder].
    Rigal A; Mouchabac S; Peretti CS
    Encephale; 2016 Dec; 42(6):568-573. PubMed ID: 27623122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antidepressant response and subthreshold bipolarity in "unipolar" major depressive disorder: implications for practice and drug research.
    Rihmer Z; Dome P; Gonda X
    J Clin Psychopharmacol; 2013 Aug; 33(4):449-52. PubMed ID: 23775059
    [No Abstract]   [Full Text] [Related]  

  • 15. Mixed-up about how to diagnose and treat mixed features in major depressive episodes.
    Stahl SM
    CNS Spectr; 2017 Apr; 22(2):111-115. PubMed ID: 28271818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scopolamine and depression: a role for muscarinic antagonism?
    Hasselmann H
    CNS Neurol Disord Drug Targets; 2014; 13(4):673-83. PubMed ID: 24938776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New insights into treatment-resistant depression. Psychotic symptoms, rather than unrecognized bipolar disorder, may underlie poor response.
    Harv Ment Health Lett; 2011 Mar; 27(9):6. PubMed ID: 21476247
    [No Abstract]   [Full Text] [Related]  

  • 18. Are Mixed Symptoms a Red Flag for Conversion of Postpartum Depression to Bipolar Disorder?
    Sharma V
    Prim Care Companion CNS Disord; 2018 May; 20(3):. PubMed ID: 29722935
    [No Abstract]   [Full Text] [Related]  

  • 19. Baseline mood-state measures as predictors of antidepressant response to scopolamine.
    Furey ML; Nugent AC; Speer AM; Luckenbaugh DA; Hoffman EM; Frankel E; Drevets WC; Zarate CA
    Psychiatry Res; 2012 Mar; 196(1):62-7. PubMed ID: 22349648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Severe depression : specific features of bipolar disorder].
    Henry C
    Encephale; 2009 Dec; 35 Suppl 7():S261-3. PubMed ID: 20141783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.